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Objective: Making a definitive preoperative diagnosis in patients with indeterminate pulmonary nodules is still
a challenge. Gene expression profiling may be a useful adjunctive diagnostic utility in this regard. We investigated
the feasibility of bronchoscopic microsampling to collect endobronchial epithelial lining fluid to obtain RNA as
a starting point for gene expression profiling.
Methods: In 15 patients, epithelial lining fluid was collected in triplicate from subsegmental bronchi close to the
pulmonary nodules and from contralateral lungs. Diagnosis was confirmed by transbronchial biopsy or surgery
(non–small cell lung cancer, n ¼ 11; benign or other lesions, n ¼ 4). Total RNA was isolated from the samples
and evaluated concerning quantity and quality. The complementary DNA was generated and analyzed by quan-
titative real-time polymerase chain reaction for potential lung cancer associated genes like matrix metalloproti-
nase (MMP9).
Results: Total RNA of adequate amount (>0.8 mg) and sufficient quality was obtained in 13 (86%) of the 15
patients. In patients with lung cancer, normalized MMP9 gene expression levels in endobronchial lining fluid
samples collected close to the lesions were in median 12 times higher than levels in the matching contralateral
samples. MMP9 expression levels were particularly high in endobronchial lining fluid samples collected from
patients with squamous cell carcinoma but not elevated in the case of benign lesions.
Conclusions: Our results show that quantitative gene expression analysis of endobronchial lining fluid collected
by bronchoscopic microsampling is both feasible and reliable and may therefore be a useful additional diagnostic
method in patients with indeterminate pulmonary nodules.Making a definitive preoperative diagnosis in patients with
indeterminate pulmonary nodules is still a challenge in clin-
ical practice. Identification of malignant nodules is impor-
tant because they represent a potentially curable form of
lung cancer.1 The prevalence of malignancy in patients
with solitary pulmonary nodules varies widely across stud-
ies. In different lung cancer screening studies the prevalence
of malignancy ranged from 2% to 13%.2 Surgery is the
diagnostic ‘‘gold standard’’ and the definitive treatment for
malignant nodules, but surgery should be avoided in patients
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benign or malignant diagnosis, but biopsy is invasive, poten-
tially risky, and frequently nondiagnostic.1
It is evident that tumor cells manipulate their environment
with respect to cell–cell and cell–extracellular matrix inter-
actions, angiogenesis, and inflammation.3 Our preclinical
study is based on the hypothesis that the adjacent tissue of
an indeterminate pulmonary nodule harbors the potential
to reveal the presence of tumor cells. We investigated
whether gene expression profiling of RNA derived from
endobronchial epithelial lining fluid (ELF) collected by
bronchoscopic microsampling may be a useful adjunctive
diagnostic method in the evaluation of patients with pulmo-
nary nodules.
PATIENTS AND METHODS
Patient Characteristics
This pilot study included 15 patients (Table 1) with indeterminate
solitary pulmonary nodules who were scheduled to undergo diagnostic
bronchoscopy at the Thoraxklinik Heidelberg between January and
June 2007. The institutional review board approved the data collection
and analysis, and written informed consent was obtained from all pa-
tients before the procedure. In all cases definitive histologic diagnosis
was established either by transbronchial biopsy or by subsequent surgi-
cal resection (adenocarcinoma, n ¼ 7; squamous cell carcinoma, n ¼ 4;
small cell lung cancer, n ¼ 1; non-Hodgkin lymphoma, n ¼ 1; and be-
nign nodule, n ¼ 2).rgery c August 2009
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B2M ¼ beta-2-microglobulin
BMS ¼ bronchoscopic microsampling
CEA ¼ carcinoembryonic antigen
ELF ¼ endobronchial lining fluid
ESD ¼ esterase D
MMP ¼ matrix metalloprotinase
NSCLC ¼ non–small cell lung cancer
qRT-PCR ¼ quantitative real-time polymerase
chain reaction
Bronchoscopic Microsampling
Bronchoscopic procedures were performed under general anesthesia
or conscious sedation in standard fashion. A variety of videobroncho-
scopes (models BF T160; Olympus; Tokyo, Japan) were used. After
complete inspection of the bronchial tree including the subsegmental
bronchi, fluoroscopy was performed and the bronchoscope was navi-
gated next to the lesion. While navigating, we placed a standard trans-
bronchial biopsy catheter in the working channel to avoid contamination
of the channel (and subsequently the sampling catheter) with ELF or
blood. ELF was sampled with the Olympus (Tokyo, Japan) mucus col-
lection probe BC-401C/BC402C (probe diameter 1.9 mm, probe length
20 mm) (Figure 1, B and C). The bronchoscopic microsampling (BMS)
device was inserted through a guided sheath into the bronchi close to
the nodule or at the contralateral site, positioned fluoroscopically. The
cotton-like tip of the collection probe device was unsheathed and left
for 10 seconds within 20 mm of the lesion (or within a bronchus of
the contralateral site). During this deployment time, the BMS device
was not further manipulated after positioning, to allow adsorption of
the lining fluid at that location. Subsequently, the ELF-containing tip
was withdrawn into the sheath of the collection probe, and both devices
were simultaneously retrieved from the lung. Immediately after retrieval
of the BMS device, the tip containing the absorbed ELF was sectioned
at the end of the stainless steel guide wire 2 cm from its end with ster-
ile scissors, placed into a reaction tube, and shock-frozen in liquidThe Journal of Thoracic andnitrogen to avoid RNA degradation. The probes were subsequently
kept at80C until further processing. In each patient, BMS procedures
were repeated in triplicate at the site of the lesion and from the contra-
lateral lung (corresponding subsegmental bronchus) as internal control.
An overview of the procedure is given in Figure 1, A.
Cytospin Preparation
From 2 patients, ELF samples were collected next to the lesion (n ¼ 6)
and from the contralateral lung (n ¼ 6). The samples were diluted with 350
mL of saline and cytocentrifuged at 1500 rpm for 10 minutes in a Shandon
Cytospin 3 cytocentrifuge (Shandon, Inc, Pittsburgh, Pa). The preparations
were May–Grunwald–Giemsa stained and analyzed by light microscopy.
Total RNA Extraction
The catheters were discarded after lysis with denaturing guanidine iso-
thiocyanate–containing buffer. Total RNA extraction was performed with
RNeasy Micro Kit (Qiagen, Hilden, Germany) according to the manufac-
turer’s instructions. The quantity of total RNA was measured by spectro-
photometer (NanoDrop Technologies, Wilmington, Del). The quality of
total RNAs was assessed with Agilent 2100 Bioanalyzer and Agilent
RNA 6000 Pico Kit (Agilent Technologies GmbH, Waldbronn, Germany).
From each patient, one ELF sample pair (lesion and contralateral site),
which yielded quality RNA (28S/18S rRNA larger than 1.0), was used
for further experiments.
Quantitative Real-Time Polymerase Chain Reaction
(qRT-PCR)
Reverse transcription was performed with 200 ng total RNA per reaction
using RevertAid First Strand cDNA Synthesis Kit (Fermentas, Burlington,
Ontario, Canada). Expression analysis of 9 genes was performed with 26
different specimens including matched indeterminate pulmonary nodule
and contralateral microsampling extracts of the same patients by qRT-
PCR (ABI Prism 7900HT Sequence Detection System; Applied Biosys-
tems, Weiterstadt, Germany). We applied gene-specific primers and probe
Taqman assays (ABI) and performed a relative quantification of all genes
by using two housekeeping genes, esterase D (ESD), which is reported to
be a suitable internal control in lung tissues, and beta-2-microglobulin
(B2M). B2M is often used for this purpose in peripheral mononuclear bloodE
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STABLE 1. Patient and nodule characteristics and total RNA quantity and quality on ELF sample preparation
Pt. no.
Age
(y) Gender
Smoking
history
(pack-years)
Histologic
diagnosis
Tumor
size (mm) Tumor location
Lesion
total RNA
(mg)
CL total
RNA
(mg)
RNA quality
28S/18S>1.0
1 65 M 80 SCC 45 3 40 Right upper lobe 1.74 1.09 Yes
2 57 F 0 NHL 170 3 130 Right upper lobe 1.32 1.57 Yes
3 58 F 15 AC 45 3 35 Right lower lobe 1.33 1.49 Yes
4 69 F 45 AC 35 3 15 Left upper lobe 1.57 2.24 Yes
5 59 M 45 SCC 50 3 45 Right lower lobe 1.44 1.04 Yes
6 62 F 0 AC 30 3 20 Left upper lobe 1.44 1.31 Yes
7 60 M 50 AC 30 3 30 Right lower lobe 1.05 1.58 Yes
8 79 F 0 AC 52 3 37 Left lower lobe 1.03 1.78 Yes
9 63 M 30 AC 30 3 20 Left upper lobe 1.66 1.09 Failed
10 57 M 80 SCLC 25 3 30 Left upper lobe 1.74 0.97 Yes
11 69 M 30 SCC 45 3 40 Left lower lobe 1.43 1.64 Yes
12 72 M 30 Benign 25 3 25 Left upper lobe 0.93 1.10 Yes
13 64 M 30 Benign 35 3 20 Right upper lobe 0.86 1.59 Yes
14 76 M 30 SCC 55 3 50 Right lower lobe 1.13 0.98 Yes
15 59 M 40 AC 30 3 20 Right upper lobe 0.60 0.49 Failed
ELF, Endobronchial lining fluid; lesion, ELF next to the indeterminate pulmonary nodule; CL, ELF from contralateral lung; SCC, squamous cell carcinoma; AC, adenocarcinoma;
NHL, non-Hodgkin lymphoma; SCLC, small cell lung cancer.Cardiovascular Surgery c Volume 138, Number 2 475
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ments for all samples was optimized by using technical triplicates from
each sample. The qRT-PCR method and analysis were described in detail
in our previous study.4 Gene expression differences between indeterminate
pulmonary nodule and contralateral microsampling extracts were analyzed
by a paired t test. Genes were regarded to be differentially expressed using
cutoff criteria of a P value< .05 and a linear fold change  2 or  0.5 for
each comparison. A detailed list of examined genes including nomenclature,
National Center for Biotechnology Information Entrez Gene ID, representa-
tive sequences of primer, and probe Taqman assays is given in Table 2.
RESULTS
BMS
Fifteen consecutive patients with fluoroscopically visible
indeterminate solitary pulmonary nodules were examined
(10 men and 5 women, median age, 69 years, range 57–79
years). The mean examination time (including subsequent
transbronchial biopsy procedures) was 15 minutes (range,
10–30 minutes). No complications occurred with the BMS
procedures. The characteristics of the 15 patients, including
age, gender, smoking history, final histologic diagnosis, tu-
FIGURE 1. A, Procedure flow chart of gene expression profiling from
endobronchial epithelial lining fluid (ELF) collected by bronchoscopic
microsampling (BMS) next to the intermediate pulmonary nodules (IPN)
and from the contralateral lung (CL) in patients with IPN. B, Image of the
end of the videobronchoscope (model BF T160, Olympus; Tokyo, Japan)
including the sheath of the Olympus Mucus Collection Probe BC-402C
with the tip in deployed position. C, The Olympus Mucus Collection Probe
BC402C (probe diameter 1.9 mm, probe length 20 mm) in more detail.476 The Journal of Thoracic and Cardiovascular Sumor size, and tumor location, are presented in Table 1. Dif-
ferential cell counts from cytospin preparations of ELF
collected by BMS revealed proportions of 50% to 80%
macrophages, 10% to 30% lymphocytes, and 5% to 15%
epithelial cells. No significant difference in the cell compo-
sition was observed between nodule site (with or without
tumor background) and contralateral site.
RNA Sample Preparation and Gene Expression
Analysis
Total RNA of adequate amount (>0.8 mg) and sufficient
quality was obtained from both ELF samples next to the
lesion and from the contralateral lung in 13 (86%) of the
15 patients. Patients 9 and 15 were excluded from further
analysis because of poor quality of the total RNA retrieved.
The total amount of RNA retrieved from ELF samples next
to the lesion and from contralateral lung of the same subject,
and results of RNA quality assessment, are presented in
Table 1. Blood cell content varied across samplings but
did not result in a systematic influence with respect to
RNA quality or qRT-PCR measurements.
We tested the reliability of gene expression analysis in
ELF samples by performing quantitative RT-PCR from
known lung cancer–associated genes that display potential
surrogate markers (KRT19, CEACAM3, CEACAM5, and
EGFR) or are involved in cell adhesion and migration
processes (MMP9, TWIST1, MUC1, and CDH1).* These
genes were frequently found to be differentially expressed
in tumor tissue versus normal tissue on the basis of results
from non–small cell lung cancer (NSCLC) gene expression
profiling studies.4 All expression values were normalized
using ESD and B2M as internal control genes. The investi-
gated transcripts have been detected in 70% to 100% of all
samples with lower (TWIST1, CEACAM3, KRT19, MMP9,
CDH1, and EGFR) or higher relative expression (B2M,
MUC1, CEACAM5, and ESD) shown in Table 2. Significant
differential expression was observed for MMP9 (P¼ .0039)
between ELF samples collected next to the lesion and contra-
lateral lung samples of patients with pulmonary nodules that
were finally diagnosed to be lung cancer (Figure 2; Table 3).
The median expression values of MMP9 in the samples
collected next to the lesion were 12-fold higher than in the
contralateral lung samples. The MMP9 expression was
more heterogeneous in adenocarcinoma but was concor-
dantly enhanced in patients with squamous cell carcinoma.
In the samples of patients with diseases other than adenocar-
cinoma or squamous cell carcinoma of the lung, MMP9 was
either lower expressed or down-regulated in samples
collected next to the lesion as compared with contralateral
*KRT19, keratin 19; CEACAM, carcinoembryonic antigen-related cell adhesion
molecule; EGFR, epidermal growth factor receptor; TWIST1, twist homolog
1 (Drosphila); MMP9, matrix metalloprotinase 9; CDH1, cadherin 1, type 1,
E-cadherin (epithelial); B2M, beta-2-microglobulin; MUC1, mucin 1 (cell surface
associated); ESD, esterase D.rgery c August 2009
Kahn et al Evolving Technology/Basic ScienceTABLE 2. Expression analysis of potential tumor-associated genes in ELF samples collected next to the lesion and from contralateral lung (CL)
using qRT-PCR
qRT-PCR Ct value ELF lesion (NSCLC) vs CL
Gene
symbol
Entrez
gene ID Assay ID Representative sequence
Median
Ct
Median
MAD
Present
values (%)
P
value
Fold
change
MMP9 4318 Hs00234579_m1 AGTACCGAGAGAAAGCCTATTTCTG 34.2 0.08 100 .0039 12.52
TWIST1 7291 Hs00361186_m1 GCCGGAGACCTAGATGTCATTGTTT 39.2 0.08 70 .0506 2.97
CEACAM3 1084 Hs00174351_m1 TCCATGTATACCAAGAAAATGCCCC 37.0 0.15 81 .2463 1.83
CDH1 999 Hs00170423_m1 CCCGCCCCATCAGGCCTCCGTTTCT 33.9 0.14 88 .4077 0.82
EGFR 1956 Hs00193306_m1 GCAGATCGCAAAGGGCATGAACTAC 32.0 0.04 100 .4205 1.40
CEACAM5 1048 Hs00237075_m1 GCATCACAGTCTCTGCATCTGGAAC 27.6 0.07 100 .4607 0.60
KRT19 3880 Hs00761767_s1 GCGTCCTGACCGCGTCCGACGGGCT 34.4 0.33 100 .5568 1.23
MUC1 4582 Hs00159357_m1 TAGCCCCTATGAGAAGGTTTCTGCA 26.4 0.02 100 .5466 1.16
ESD (HK) 2098 Hs00382661_m1 CTCCGCCACCGTAGAATCGCCTACC 29.6 0.03 100 .3694 0.90
B2M (HK) 567 Hs99999907_m1 TAAGTGGGATCGAGACATGTAAGCA 23.8 0.03 100 .3694 1.11
All genes are expressed in the majority of the endobronchial lining fluid (ELF) samples with median cycle threshold (Ct) values between 23 and 39, and low median absolute
deviations (MAD). Paired t test was performed for all lesions identified as non–small cell lung cancer (NSCLC) tumors to identify differentially expressed genes (P value
<.05; linear median fold change>2). qRT-PCR, quantitative real-time polymerase chain reaction; ID, identification; ESD (HK), esterase D (Hong Kong); B2M (HK), beta-2-micro-
globulin (Hong Kong); MMP9, matrix metalloprotinase 9; TWIST1, twist homolog 1 (Drosphila); CEACAM, carcinoembryonic antigen-related cell adhesion molecule; CDH1,
cadherin 1, type 1, E-cadherin (epithelial); EGFR, epidermal growth factor receptor; KRT19, keratin 19; MUC1, mucin 1 (cell surface associated).E
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according to expression heterogeneity among all ELF sam-
ples (Table 2).
DISCUSSION
Solitary pulmonary nodules are a frequent incidental find-
ing because of current widespread use of computed tomogra-
phy in the investigation of respiratory symptoms. However,
as imaging techniques improve and more nodules are de-
tected, the optimal management of these nodules remains un-
clear. Current tests for the diagnosis of solitary pulmonary
nodules, with regard to their performance characteristics
and complication rates, are far from ideal. Bronchoscopic
FIGURE 2. Using quantitative real-time polymerase chain reaction, differ-
ential expression was observed for MMP9 between endobronchial epithelial
lining fluid samples collected by bronchoscopic microsampling next to the
lesion and from the contralateral lung of patients with pulmonary nodules
that were finally diagnosed to be lung cancer (P ¼ .0039). All expression
values were normalized using ESD and B2M as internal control genes.
SCC, Squamous cell carcinoma; SCLC, small cell lung cancer; NHL, non-
Hodgkin lymphoma; Pat ID, patient identification.The Journal of Thoracic andor computed tomography–guided tissue sampling often
yields a specific malignant diagnosis but suffers from sam-
pling bias, which dictates additional workup if biopsy results
are nondiagnostic in patients with a high pretest probability
of malignancy. The associated pneumothorax rate, albeit
high, infrequently leads to significant morbidity.1,2
The major advantage of the BMS probe used in this study
is that it is less invasive than transbronchial biopsy or needle
TABLE 3. The qRT-PCR result for MMP9 indicates upregulation in
the ELF lesion of the patients with NSCLC compared with the
matched contralateral samples
MMP9 qRT-PCR ELF lesion vs ELF CL
Pt. no.
Histologic
diagnosis
Expression
level Error
1 SCC 38.23 2.52
2 NHL 1.42 0.18
3 AC 2.36 0.17
4 AC 2.09 0.11
5 SCC 116.54 1.16
6 AC 49.75 2.41
7 AC 0.40 0.54
8 AC 17.27 0.75
9 AC N/A N/A
10 SCLC 0.46 0.12
11 SCC 60.26 1.96
12 Benign 0.57 0.21
13 Benign 0.28 0.24
14 SCC 16.47 0.07
15 AC N/A N/A
Expression level, Relative quantification between endobronchial lining fluid (ELF)
lesion and ELF contralaateral lesion (CL) using housekeeping genes esterase D
(ESD) and beta-2-microglobulin (B2M) for normalization; error, error continuation
calculated by median absolute deviation of technical triplicate measurements of
each sample. qRT-PCR, Quantitative real-time polymerase chain reaction; MMP9, ma-
trix metalloprotinase; SCC, squamous cell carcinoma; NHL, non-Hodgkin lymphoma;
AC, adenocarcinoma; SCLC, small cell lung cancer; N/A, not available.Cardiovascular Surgery c Volume 138, Number 2 477
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setting.5-9 The probe allows quantitative sampling of epithe-
lial ELF from subsegmental bronchi near the nodule during
bronchoscopy. Watanabe and colleagues10 were the first to
evaluate the potential application of that probe in the evalu-
ation of pulmonary nodules. They could demonstrate that
there were significantly higher concentrations of cytokeratin
19 and carcinoembryonic antigen (CEA) proteins in ELF
next to peripheral lung adenocarcinomas, compared with
levels detected in ELF retrieved from contralateral lung of
the same subjects and the lungs of individuals who did not
have lung cancer. It is intriguing that CYFRA and CEA
from ELF samples marked the malignant nodules even
when serum levels were not elevated.10 To explain this phe-
nomenon, one may hypothesize that markers released from
small peripheral malignant tumors of the lung would be di-
luted away in epithelial ELF to levels indistinguishable from
background concentrations. The microsampling probe, how-
ever, would soak up small samples of ELF near the periph-
eral nodule during bronchoscopy.10
The results of the present study suggest that measure-
ments of specific tumor-associated genes in ELF samples
collected by BMS can detect lung cancer among patients
with indeterminate solitary pulmonary nodules. The data in-
dicate that RNA in adequate amounts and quality for further
gene expression analysis can be extracted from the majority
of ELF samples collected by BMS. This concept may open
the way to screen for new biomarkers and to improve the
accurate and early detection of lung cancer, potentially elim-
inating more risky invasive procedures now commonly used
to distinguish benign from malignant nodules. In 2 of 15
patients, ELF sample pairs could not be further analyzed.
This indicates that improvements of the microsampling pro-
cedure, for example, optimization of distance, time, and
performance of ELF sampling, are required.
A limited number of genes, potential tumor markers and
controls, were analyzed to demonstrate the feasibility of
our workflow and to unravel expression changes in ELF
samples next to the tumor lesion. We found MMP9 gene
expression levels in ELF samples collected next to NSCLC
lesions to be in median 12 times higher than levels detected
in ELF retrieved from the contralateral lung of the same sub-
jects. Moreover, in the 4 cases of squamous cell carcinoma,
MMP9 gene expression was in the range of 50 (median)
times higher in the ELF lesion compared with the contralat-
eral site. In contrast, MMP9 expression levels were not ele-
vated in ELF samples collected from patients with benign
lesions. Matrix metalloproteinase (MMP)–mediated degra-
dation of the extracellular matrix is a key mechanism in
tumor growth and invasion, and MMP9 expression levels
were found to be increased in NSCLC tumor tissues.11,12
The gene was markedly overexpressed in squamous cell car-
cinoma compared with adenocarcinoma and normal tissue.13
Moreover, increased serum levels of MMP9 were found to478 The Journal of Thoracic and Cardiovascular Sube predictive of disease progression in patients with
advanced NSCLC.14-17 From our preliminary data it may
be hypothesized that increased MMP9 levels detected in
ELF sampled next to an NSCLC lesion would derive from
macrophages collected alongside the epithelial ELF. In our
study, cytospin preparations from microsampling specimens
revealed proportions of 50% to 80% macrophages among
cells collected. It has been shown that tumor-associated
macrophages express MMP9 and that MMP9-expressing
tumor-associated macrophages play a key role in preparing
premetastatic sites for eventual malignant cell growth in
a manner dependent on vascular endothelial growth factor
receptor-1.18,19 Moreover, increased expression of mRNA
tissue inhibitor of matrix metalloproteinase-1 in nontumo-
rous surrounding lung tissue of resected NSCLC was dem-
onstrated, suggesting that MMP-induced changes may be
detectable in normal lung tissue next to NSCLC lesions.20
On the other hand, messenger RNA levels from other genes
that were frequently found to be overexpressed in NSCLC
tumor tissues, including KRT19, CEACAM3, CEACAM5,
EGFR, TWIST1, MUC1, and CDH1, were not found to be
concordantly increased in ELF samples collected next to
NSCLC lesions compared with ELF retrieved from the con-
tralateral lung of the same subjects or the lungs of patients
with benign lesions. One reason for this may be the low pro-
portion of epithelial cells in ELF samples and the impact of
noise deriving from a more heterogeneous expression in
macrophages and lymphocytes. Thus, classic tumor cell–de-
rived candidate genes may be of limited use when investigat-
ing ELF samples on the transcriptional level, indicating the
need of novel target genes and a screening approach specific
for BMS sampling.
In conclusion, our results show that gene expression anal-
ysis of ELF collected by BMS is both feasible and reliable,
and measurements of specific tumor-associated genes in
ELF samples may be a useful additional diagnostic method
in patients with indeterminate pulmonary nodules. Of note,
our pilot study did not establish a new standard procedure
for the management of patients with indeterminate pulmonary
nodules: Larger studies are required to warrant a departure
from this novel diagnostic method into clinical routine.
Because of the specific characteristics of ELF discussed
herein, however, adequate biomarkers or biomarker combina-
tions with the highest predictive value still need to be identified
and validated for this particular method in a larger collective.
We thank Mrs Elisabeth Chang Xu and Sabrina Balaguer for
their expert technical assistance. The microsampling probes were
generously supplied by Olympus Ltd, Tokyo, Japan.
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